Castle Creek Biosciences, Inc., a late-stage cell and gene therapy company, is using lentiviral vector delivery platforms to develop and commercialize therapies for a broad range of genetic diseases. As a leader in lentiviral delivered strategies, our scientists are utilizing ex vivo and in vivo technologies to switch gene targets and create optimal therapies that address the distinctive needs of each targeted indication, initially skin, connective tissue and metabolic diseases.
To leverage the science behind our lentiviral vector delivery platforms with our manufacturing experience to create transformative therapies and improve lives of people living with genetic diseases.
Castle Creek Biosciences is a portfolio company of Paragon Biosciences.
Paragon is a global life science leader that creates, builds and funds innovative biology-based companies. It uses biology to accelerate scientific breakthroughs to treat and cure diseases.
We are inspired by people who are impacted by genetic diseases with limited or no therapeutic options. Our current focus is on dystrophic epidermolysis bullosa (DEB), hereditary tyrosinemia type 1 (HT1), Ehlers-Danlos syndrome (EDS), and osteogenesis imperfecta (OI), with the goal of expanding our pipeline to other therapeutic areas, including inborn errors of metabolism.
Tailoring our therapeutic approach for the unique needs of each targeted indication
